Is there a vaccine against RSV? After nearly 60 years, many potential candidates came at the same time

Published Date: 02 Mar 2023

You may not have heard of respiratory syncytial virus (RSV). However, it killed more than 100,000 people worldwide in 2019, making it the leading cause of death among children under the age of one.

Read Full News

Latest News

Who’s In Charge in the ICU? Families Need to Know

In the Arab region, families often meet intensivists for the first time in a crisis — adding confusion when trust and clear ICU decisions matter most.

JAK Inhibitors: Putting Safety Concerns in Context

After a study revealed higher cancer and other risks with a JAK inhibitor in patients with rheumatoid arthritis, further evidence suggests that the risks may be lower in dermatology.

High-Dose Flu Vaccine Linked to Lower Dementia Risk

Vaccination with a higher dose of the influenza vaccine may reduce the risk of developing dementia among older adults.

New Drugs Are Primary Care Game Changers, but Pricey

Four recent approvals are poised to affect patient care.

Life-Extending Bile Duct Cancer Drug Cleared for NHS Use

NICE has recommended zanidatamab for HER2-positive biliary tract cancer in final draft guidance, offering patients more time and better quality of life.

SARS-CoV-2 Tied to Higher Respiratory Failure Risk Than Flu

Hospitalised adults with SARS-CoV-2, parainfluenza virus, or RSV vs influenza A/B infection experience greater acute respiratory failure, with those with SARS-CoV-2 infection having the greatest risk.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Latest News

In the Arab region, families often meet intensivists for the first time in a crisis — adding confusion when trust and clear ICU decisions matter most.

After a study revealed higher cancer and other risks with a JAK inhibitor in patients with rheumatoid arthritis, further evidence suggests that the risks may be lower in dermatology.

Vaccination with a higher dose of the influenza vaccine may reduce the risk of developing dementia among older adults.

Four recent approvals are poised to affect patient care.

NICE has recommended zanidatamab for HER2-positive biliary tract cancer in final draft guidance, offering patients more time and better quality of life.

Hospitalised adults with SARS-CoV-2, parainfluenza virus, or RSV vs influenza A/B infection experience greater acute respiratory failure, with those with SARS-CoV-2 infection having the greatest risk.

News All Time

Dendritic Cell Strategies May Reduce Cancer Recurrence Risk

Dendritic cells within tumors may enable personalized immunotherapy strategies that reduce the risk for cancer relapses by strengthening immune memory.

Sunflower Seed Sensitization Outpaces True Allergy in Kids

More than 80% of children sensitized to sunflower seeds and advised to avoid them can tolerate the seeds during an oral food challenge.

Adding Steroid Shows No Heart Benefit in Kawasaki Disease

Adding prednisolone to the standard treatment for Kawasaki disease in children does not lower the incidence of coronary artery lesions at 1 month after illness onset, according to a phase 3 trial.

Torque Teno Virus Predicts Malignancy Post-Kidney Transplant

Higher torque teno virus loads during the first year after kidney transplant are associated with an increased risk for malignancies in subsequent years, a prospective study finds.

Allergy Myths Abound on Social Media: Debunk With Care

From probiotics to do-it-yourself IgG test kits, social media is misinforming patients about how to diagnose and manage allergies.

Precision Medicine for Rare Allergies

New biologics, precision diagnostics, and AI are reshaping care for rare allergies — from eosinophilic esophagitis to drug hypersensitivity — moving practice toward personalized treatment.

NICE Backs Belantamab Mafodotin for Relapsed Myeloma

NICE has recommended belantamab mafodotin for relapsed multiple myeloma, with trial data showing remissions of more than 3 years.

Study Identifies Novel Stress-Inflammation Pathway in AD

Most patients and doctors know that stress exacerbates AD. A new study pinpoints a neural mechanism that may be involved in this process.

Scotland Backs New Immunotherapy in Advanced Cervical Cancer

The Scottish Medicines Consortium has accepted pembrolizumab with chemoradiotherapy for high-risk, locally advanced cervical cancer in Scotland.

Eye Shingles Tied to Cancer Risk in Those With Immune Issues

Herpes zoster ophthalmicus is associated with an increased risk for subsequent malignancy among individuals with an underlying history of immune dysregulation, according to a recent cohort study.

Novo Nordisk Weight-loss Drug Shows Liver Benefits in Mouse Study

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)

SLIT Adherence May Lower Rhinitis Severity in Children

Higher adherence to sublingual pollen immunotherapy in children with allergic rhinitis is linked to lower odds of severe rhinitis.

Schistosomiasis: Four Things You May Not Know

From Ancient Egypt to Modern China, how parasitic worms have shaped human health and world history.

C auris Is Now Endemic in Europe. Can It Be Contained?

The fungus, identified only 20 years ago, is endemic in healthcare facilities of five European countries. What can be done to stop its spread?

New Pulmonary Embolism Clinical Categories PCPs Should Know

Dr Nina Lum discusses key takeaways of new PE clinical categories for primary care physicians and providers.

Amgen's Lung Cancer Drug Tarlatamab Wins China Approval

Amgen's lung cancer drug tarlatamab has won ⁠approval from China's National Medical Products Administration.

Recommended News For You

In KRAS-mutated non-small cell lung cancer, glecirasib exhibits promising efficacy.

The main subject is associated with suicide in the United States.

Immunotherapy-TACE Regimen Boosts PFS in Unresectable Liver Cancer

Zebrafish models offer fast, effective guidance for personalized therapies for kids with high-risk cancer

If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version

Chemo causes lasting physical decline in breast cancer survivors

A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.

Recommended Articles For You

Unlocking the Mysteries of the Axillary Vein: Exploring its Role in Human Anatomy 

The Mysterious Pain of Scrotal Hematoma: A Guide to Diagnosis and Treatment 

Deterministic Reprogramming of Neutrophils within Tumors: A New Frontier in Cancer Research 

A Review of Cancer Treatment Evolution Towards Stem Cells and Gene Therapy 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most

2.

The Truth About Apple AirPods

3.

Too Many Kids With Sickle Cell Disease Aren't Getting Appropriate Preventive Care

4.

Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.

5.

Investigating the Relationship Between GERD and Anxiety/Depression.

1.

Understanding the HAS-BLED Score: What It Is and Why It Matters 

2.

Unlocking a New Era in Bladder Cancer Treatment: A Review of the TAR-200 Intravesical Drug Delivery System

3.

Exploring the Causes and Treatments of Thrombocytopenia: A Comprehensive Guide

4.

Everything You Need to Know About the Latest Hyponatremia Algorithm 

5.

Understanding SVR Normal Range: A Guide to Achieving Optimal Health

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

2.

Efficient Management of First line ALK-rearranged NSCLC - Part VIII

3.

Managing CNS diseases at the point of diagnosis in ALK + NSCLC

4.

Updates on the First Line Management of ALK+ NSCLC

5.

Efficient Management of First line ALK-rearranged NSCLC - Part VII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot